Id: | acc1132 |
Group: | 2sens |
Protein: | p70S6K |
Gene Symbol: | RPS6KB1 |
Protein Id: | P23443 |
Protein Name: | KS6B1_HUMAN |
PTM: | phosphorylation |
Site: | Thr421 |
Site Sequence: | TYVAPSVLESVKEKFSFEPKI |
Disease Category: | Cancer |
Disease: | Gastric Cancer |
Disease Subtype: | |
Disease Cellline: | SGC7901 |
Disease Info: | |
Drug: | 5-aza |
Drug Info: | "5-aza, also known as 5-azacytidine, is a chemical compound used in the treatment of certain hematological diseases, notably myelodysplastic syndromes, and acts by inhibiting DNA methylation." |
Effect: | inhibit |
Effect Info: | "In cells treated with LY294002 or RAPA, the phosphorylation of Akt, p70S6K, and 4E - BP1 was significantly reduced, which enhanced the effects of 5 - aza - dC on cell proliferation and cell cycle arrest in human gastric cancer cell lines." |
Note: | |
Score: | 5.0 |
Pubmed(PMID): | 18622747 |
Sentence Index: | 18622747_10-11 |
Sentence: | "Phosphorylation of Akt, p70S6K and 4E-BP1 were significantly reduced in the cells treated with LY294002 or RAPA (P<0.01), but we failed to find that 5-aza-dC enhance these effects. We suggested that mTOR inhibition could enhance the effects of 5-aza-dC on suppressing cell proliferation and arresting cell cycle in human gastric cancer cell lines, which might be a potential target for tumor therapy." |
Sequence & Structure:
MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
RPS6KB1 | TAS0612 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Recruiting | neoplasm | ClinicalTrials |
RPS6KB1 | MSC-2363318A | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Completed | neoplasm | ClinicalTrials |
RPS6KB1 | LY-2780301 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Completed | lymphoma | ClinicalTrials |
RPS6KB1 | XL-418 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Suspended | neoplasm | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | renal cell carcinoma | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | non-small cell lung carcinoma | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | metastasis | ClinicalTrials |
RPS6KB1 | LY-2780301 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Completed | metastasis | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | neuroendocrine neoplasm | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Completed | cancer | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | cancer | ClinicalTrials |
RPS6KB1 | XL-418 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Suspended | cancer | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACRPS6KB1-Thr421 | |
---|---|
Cancer | Intensity |
BRCA | -1.122 |
COAD | 1.552 |
HGSC | |
ccRCC | -1.395 |
GBM | -0.379 |
HNSC | 0.47 |
LUAD | -0.284 |
LUSC | 0.124 |
non_ccRCC | |
PDAC | -0.319 |
UCEC | 1.351 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 421 | U | Alzheimer's disease | Phosphorylation | 16364302 |
T | 421 | U | Pancreatic ductal adenocarcinoma | Phosphorylation | 27014871 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.